ArticlePeerJ2020
Prevalence and type distribution of human papillomavirus in a Chinese urban population between 2014 and 2018: a retrospective study.
Article in PeerJ, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Epidemiology of high-risk human papillomavirus among women of the north-central region of Ecuador: a retrospective study.Infectious agents and cancer · 2025Article
- HPV infection trends in Inner Mongolia across the pre- and pandemic periods of COVID-19: A single-center analysis.Medicine · 2025Article
- Characterization of human papillomavirus genotypes infections in patients with cervical lesions and cervical cancer in Urumqi, Xinjiang from 2016 to 2023.Virology journal · 2025Article
- Prevalence and type distribution of human papillomavirus in a Chinese urban population between 2019 and 2023: a retrospective study.Frontiers in microbiology · 2025Article
- Detecting and genotyping high-risk human papillomavirus among male patients during 2015-2023 in Beijing, China.Emerging microbes & infections · 2024Article
- HPV genotypes in invasive cervical cancer: prevalence, risk attribution, and optimized vaccine strategies in western China.Frontiers in public health · 2024Article
- hnRNP E1 Regulates HPV16 Oncogene Expression and Inhibits Cervical Cancerization.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman papilloma virus (HPV) infection is one of the most common sexually transmitted infections among women worldwide. The current study's main objective is to report the prevalence and distribution of HPV types in an urban population in Beijing, China.
methodsAll the eligible female participants aged ≥18 years were recruited from the Aerospace Center Hospital in Beijing, China between 2014 and 2018. A total of 21 HPV types were detected by the polymerase chain reaction (PCR) reverse dot blot method and fluorescence quantitative PCR method.
resultsIn total, 12 high risk HPV types and nine low risk HPV types were detected. The HPV-positive rates were 8.85% in 2014, 7.16% in 2015, 7.60% in 2016, 8.31% in 2017, and 7.72% in 2018, respectively, in an urban population in Beijing, China. Overall, no significant differences in the HPV-positive rates were found over the five years. The peak prevalence of HPV infection in all types was observed in age group of 20-24 in all types. HPV52 was the dominant HPV type across the five years . Among all 21 HPV types, HPV66, HPV26, and HPV59 were ranked the top three in coinfection occurrence.
conclusionsOur findings are very helpful for HPV screening and vaccination. The associations between gynaecological diseases and the HPV types with high prevalence, particularly HPV52, warrant further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.